Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
A. O. Smith Corporation · AOS · FY2026 Q1 · Calendar Q2 2026
A. O. Smith's fiscal Q1 2026 marked a clear deterioration from the record pace of 2025. EPS of $0.85 missed consensus by 9.8% and revenue of $945.6 million fell short by 2.9%, driven by an 11% decline in Rest of World sales as China demand weakened further. Management lowered full-year EPS guidance to $3.70-$4.00 from the $3.85-$4.15 range set in Q4 2025, with downward revisions to water-treatment growth (now 5-6%) and China sales (now low double-digit decline). Offsetting measures include announced 4-7% Q3 price increases, a water-treatment restructuring targeting $6-8 million in annual savings from 2027, and $119 million in free cash flow. The DOE's delay of the commercial water-heater rule to October 2027 altered pre-buy dynamics, and Leonard Valve contributed $16 million in its first partial quarter. The market reacted negatively: a 3.9% abnormal decline on the event session…
A. O. Smith Corporation (AOS) is a global manufacturer and marketer specializing in a comprehensive array of water heating and treatment solutions. Its operations span North America, China, Europe, and India, organized into two primary geographic segments: North America and Rest of World. The company's product portfolio is extensive, featuring residential and commercial water heaters (gas, heat pump, and electric models), boilers, storage tanks, and various water treatment systems. These products cater to a wide range of applications, including homes, apartments, and condominiums, as well as commercial entities such as restaurants, hotels, office buildings, laundries, car washes, small businesses, hospitals, and schools.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Stifel | Buy | Buy | Maintain | Jul 20, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Jun 10, 2026 |
| JP Morgan | Underweight | Neutral | Downgrade | May 15, 2026 |
| DA Davidson | Neutral | Neutral | Maintain | May 4, 2026 |
| Citigroup | Neutral | Neutral | Maintain | May 4, 2026 |
| Baird | Neutral | Neutral | Maintain | May 1, 2026 |
| Goldman Sachs | Sell | Sell | Maintain | Apr 13, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 28, 2025 |
| Jefferies | Hold | Hold | Maintain | Apr 12, 2024 |
| Northcoast Research | Buy | Neutral | Upgrade | Dec 12, 2023 |
| Loop Capital | Hold | Buy | Downgrade | Jan 17, 2023 |
| Longbow Research | Buy | Neutral | Upgrade | Jul 6, 2022 |
| CFRA | Hold | Hold | Maintain | Jan 27, 2022 |
| Rosenblatt | Buy | Buy | Maintain | Jul 16, 2021 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | May 7, 2020 |
| Boenning & Scattergood | Outperform | Neutral | Upgrade | May 6, 2020 |
| Keybanc | Overweight | Downgrade | Dec 9, 2019 | |
| Edward Jones | Hold | Buy | Downgrade | May 20, 2019 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jan 30, 2019 |
| BMO Capital | Market Perform | Outperform | Downgrade | Jan 30, 2019 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 27, 2018 |
| Maxim Group | Hold | Buy | Downgrade | Jan 8, 2016 |
| Wedbush | Neutral | Outperform | Downgrade | Jan 28, 2015 |
| Northland Capital Markets | Market Perform | Outperform | Downgrade | Jan 5, 2015 |
| Northland | Market Perform | Outperform | Downgrade | Jan 5, 2015 |
| Sterne Agee | Buy | Neutral | Upgrade | Apr 22, 2014 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Apr 24, 2013 |
| Janney Capital | Buy | Neutral | Upgrade | Apr 24, 2013 |
| Sidoti & Co. | Neutral | Buy | Downgrade | Oct 18, 2012 |
Upside is calculated against the persisted current price $60.13. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Stifel Nicolaus | Nathan Jones | $76 | $58.85 | +26.4% | Jul 20, 2026 |
| Oppenheimer | Analyst unavailable | $75 | $59.23 | +24.7% | Jun 10, 2026 |
| D.A. Davidson | Analyst unavailable | $67 | $59.61 | +11.4% | May 4, 2026 |
| Robert W. Baird | Analyst unavailable | $70 | $60.36 | +16.4% | May 1, 2026 |
| Oppenheimer | Bryan Blair | $80 | $60.32 | +33.0% | May 1, 2026 |
| Stifel Nicolaus | Nathan Jones | $75 | $61.84 | +24.7% | May 1, 2026 |
| Stifel Nicolaus | Nathan Jones | $78 | $67.18 | +29.7% | Apr 14, 2026 |
| Goldman Sachs | Susan Maklari | $69 | $79.62 | +14.8% | Feb 12, 2026 |
| D.A. Davidson | Matt Summerville | $75 | $74.31 | +24.7% | Feb 2, 2026 |
| Stifel Nicolaus | Nathan Jones | $85 | $73.17 | +41.4% | Jan 30, 2026 |
| Robert W. Baird | Michael Halloran | $77 | $73.17 | +28.1% | Jan 30, 2026 |
| Jefferies | Analyst unavailable | $75 | $70.4 | +24.7% | Jan 9, 2026 |
| Stifel Nicolaus | Analyst unavailable | $80 | $66.36 | +33.0% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $76 | $66.84 | +26.4% | Oct 29, 2025 |
| UBS | Damian Karas | $74 | $67.3 | +23.1% | Jan 31, 2025 |
| Oppenheimer | Bryan Blair | $88 | $68.3 | +46.3% | Jan 14, 2025 |
| Robert W. Baird | Michael Halloran | $81 | $78.21 | +34.7% | Oct 23, 2024 |
| D.A. Davidson | Matt Summerville | $80 | $78.21 | +33.0% | Oct 23, 2024 |
| UBS | Damian Karas | $80 | $78.21 | +33.0% | Oct 23, 2024 |
| CFRA | Emily Nasseff Mitsch | $90 | $78.21 | +49.7% | Oct 22, 2024 |
| Robert W. Baird | Michael Halloran | $82 | $80.87 | +36.4% | Oct 14, 2024 |
| Stifel Nicolaus | Nathan Jones | $98 | $82.18 | +63.0% | Jul 24, 2024 |
| Stifel Nicolaus | Nathan Jones | $97 | $90.14 | +61.3% | Jul 18, 2024 |
| UBS | Damian Karas | $75 | $80.86 | +24.7% | Jul 8, 2024 |
| Jefferies | Saree Boroditsky | $90 | $86.31 | +49.7% | Apr 12, 2024 |
| UBS | Damian Karas | $64 | $58.45 | +6.4% | May 20, 2022 |
Track every rating change on AOS the moment it posts. Free to start.
Start freeFollow AOS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompared to Q4 2025, management tone shifted from confident to cautious. Full-year 2026 EPS guidance was lowered from $3.85-$4.15 to $3.70-$4.00. Water-treatment growth was revised down to 5-6%, and the China sales outlook worsened to a low double-digit decline. Q1 EPS of $0.85 fell 11% year-over-year, ending the record earnings streak. The DOE delayed commercial water-heater rule enforcement from October 2026 to October 2027, altering pre-buy dynamics. Leonard Valve, acquired in Q4 2025, contributed $16 million in Q1 sales.
Full-year 2026 EPS range lowered from $3.85-$4.15 to $3.70-$4.00. Water-treatment growth revised down to 5-6%. China sales outlook worsened to low double-digit decline. Capex unchanged at $70-$80 million. Share repurchase target set at $200 million annually.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.